Post-Marketing Safety Surveillance of the Salvia Miltiorrhiza Depside Salt for Infusion: A Real World Study

Ying-Ying Yan, Yi-Heng Yang, Wei-Wei Wang, Yu-Ting Pan, Si-Yan Zhan, Ming-Yang Sun, Hong Zhang, Suo-Di Zhai, Ying-Ying Yan, Yi-Heng Yang, Wei-Wei Wang, Yu-Ting Pan, Si-Yan Zhan, Ming-Yang Sun, Hong Zhang, Suo-Di Zhai

Abstract

Background: Salvia Miltiorrhiza Depside Salt for Infusion (SMDS) is made of a group of highly purified listed drugs. However, its safety data is still reported limitedly. Compared with the clinical trials, its safety in the real world setting is barely assessed.

Objective: To investigate the safety issues, including adverse events (AEs), adverse events related to SMDS (ADEs), and adverse drug reactions (ADRs) of the SMDS in the real world clinical practice.

Methods: This is a prospective, multicenter, pharmacist-led, cohort study in the real world setting. Consecutive patients prescribed with SMDS were all included in 36 sites. Pharmacists were well trained to standardized collect the patients information, including demographics, medical history, prescribing patterns of SMDS, combined medications, adverse events, laboratory investigations, outcomes of the treatment when discharge, and interventions by pharmacists. Adverse events and adverse drug reactions were collected in details. Multivariate possion regression analysis was applied to identify risk factors associated with ADEs using the significance level (α) 0.05. ClinicalTrials.gov Identifier: NCT01872520.

Results: Thirty six hospitals were participated in the study and 30180 consecutive inpatients were included. The median age was 62 (interquartile range [IQR], 50-73) years, and male was 17384 (57.60%) among the 30180 patients. The incidences of the AEs, ADEs and ADRs were 6.40%, 1.57% and 0.79%, respectively. There were 9 kinds of new ADEs which were not on the approved label found in the present study. According to the multivariate analysis, male (RR = 1.381, P = 0.009, 95%CI [1.085~1.759]), more concomitant medications (RR = 1.049, P<0.001, 95%CI [1.041~1.057]), longer duration of SMDS therapy (RR = 1.027, P<0.001, 95%CI [1.013~1.041]), higher drug concentration (RR = 1.003, P = 0.014, 95%CI [1.001~1.006]), and resolvent unapproved (RR = 1.900, P = 0.002, 95%CI [1.260~2.866]) were the independent risk factors of the ADEs. Moreover, following the approved indication (RR = 0.655, P<0.001, 95%CI [0.532~0.807]) was associated with lower incidence of ADEs.

Conclusions: SMDS was well tolerated in the general population. The incidences of the AEs, ADEs and ADRs were 6.40%, 1.57% and 0.79%, respectively. Several risk factors of its ADEs have been identified. It is recommended to follow the instructions when prescribing and administrating SMDS in the real world clinical practice.

Conflict of interest statement

We have the following interests: This study was partially supported by the Shanghai Green Valley Pharmaceutical Co, Ltd. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Figures

Fig 1. Flow chart of data collection.
Fig 1. Flow chart of data collection.
Fig 2. Flow chart in identifying ADRs/AEs…
Fig 2. Flow chart in identifying ADRs/AEs by pharmacists.

References

    1. Ji KM, Chen JJ, Li M, Liu ZG, Xia LX, Wang CB, et al. Comments on serious anaphylaxis caused by nine Chinese herbal injections used to treat common colds and upper respiratory tract infections. Regul Toxicol Pharm. 2009; 55: 134–138.
    1. Ji KM, Li M, Chen JJ, Zhan ZK, Liu ZG. Anaphylactic shock and lethal anaphylaxis caused by Houttuynia Cordata injection, a herbal treatment in China. Allergy. 2009;64: 816–817. 10.1111/j.1398-9995.2009.01942.x
    1. China Food and Drug Administration. The annual report of the national adverse drug reaction monitoring system (2014). 2014. Available: . Accessed 24 Otc 2015.
    1. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45: 1345–1359. 10.1177/0091270005282630
    1. Wang J, Xiong X, Feng B. Cardiovascular effects of magnesium salvianolate B. Evid Based Complement Alternat Med. 2013: 247948.
    1. Li X, Yu C, Sun W, Liu G, Jia J, Wang Y. Simultaneous determination of magnesium lithospermate B, rosmarinic acid, and lithospermic acid in beagle dog serum by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 200418: 2878–2882. 10.1002/rcm.1703
    1. Qin CZ, Ren X, Zhou HH, Mao XY, Liu ZQ. Inhibitory effect of SMDS on human cytochrome P450 3A4 in vitro involving a noncompetitive manner. Int J Clin Exp Med. 2015;8: 15549–15555.
    1. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39: 44–84. 10.1016/j.biocel.2006.07.001
    1. Jia JY, Lu YL, Li XC, Liu GY, Li SJ, Liu Y, et al. Pharmacokinetics of depside salts from Salvia miltiorrhiza in healthy Chinese volunteers: A randomized, open-label, single-dose study. Curr Ther Res Clin Exp. 2010;71: 260–271. 10.1016/j.curtheres.2010.08.004
    1. Miao Y, Gao Z,Xu F, Wang X, Chen K, Zhang D. Clinical observation on SMDS for the treatment of angina pectoris in coronary heart disease with heart-blood stagnation syndrome. Traditional chinese drug research and clinical pharmacology. 2006;02:140–14.
    1. Shan Y, Fan W, Qi W, Zheng Q, He Y, Ren X. SMDS injection in treatment of senile stable angina pectoris. Chin J of Geriatr Heart Brain Vessel Dis. 2013;02:135–138.
    1. Saturni S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N, et al. Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther. 2014;27: 129–138. 10.1016/j.pupt.2014.01.005
    1. Jegou D, Penninckx F, Vandendael T, Bertrand C, Van Eycken E. Completeness and registration bias in PROCARE, a Belgian multidisciplinary project on cancer of the rectum with participation on a voluntary basis. Eur J Cancer. 2015;51: 1099–1108. 10.1016/j.ejca.2014.02.025
    1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356: 1255–1259. 10.1016/S0140-6736(00)02799-9
    1. WHO Collaborating Centre for International Drug Monitoring, Uppsala. The use of the WHO-UMC system for standardised case causality assessment. Avaliable: . Accessed 24 Otc 2015.
    1. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49: 2229–2232.
    1. Li XL, Tang JF, Li WX, Li CX, Zhao T, Zhao BC. et al. Postmarketing Safety Surveillance and Reevaluation of Danhong Injection: Clinical Study of 30888 Cases. Evid Based Complement Alternat Med. 2015: 610846 10.1155/2015/610846
    1. Zhang L, Wong LYL, He Y, Wong ICK. Pharmacovigilance in China: Current Situation, Successes and Challenges. Drug Safety. 2014;37: 765–770. 10.1007/s40264-014-0222-3
    1. Liu J, Zhou ZL, Yang SM, Feng BL, Zhao J, Liu H, et al. Factors that affect adverse drug reaction reporting among hospital pharmacists in Western China. Int J Clin Pharm. 2015;37: 457–464. 10.1007/s11096-015-0065-8
    1. Su CH, Ji H, Su YX. Hospital pharmacists' knowledge and opinions regarding adverse drug reaction reporting in Northern China. Pharmacoepidemiology and Drug Safety 2010;19: 217–222. 10.1002/pds.1792
    1. Borden EK, Lee JG. A Methodologic Study of Post-Marketing Drug-Evaluation Using a Pharmacy-Based Approach. J Chron Dis. 1982;35: 803–816.
    1. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26: 546–550. 10.1007/s11606-010-1609-1
    1. Liu YR, Qu SX, Maitz MF, Tan R, Weng J. The effect of the major components of Salvia Miltiorrhiza Bunge on bone marrow cells. J Ethnopharmacol. 2007;111:573–83. 10.1016/j.jep.2007.01.005
    1. Zhang XZ, Qian SS, Zhang YJ, Wang RQ. Salvia miltiorrhiza: A source for anti-Alzheimer's disease drugs. Pharm Biol. 2015: 1–7.
    1. Zhou X, Cheung CM, Yang JM, Or PM, Lee WY, Yeung JH. Danshen (Salvia miltiorrhiza) water extract inhibits paracetamol-induced toxicity in primary rat hepatocytes via reducing CYP2E1 activity and oxidative stress. J Pharm Pharmacol. 2015;67: 980–989. 10.1111/jphp.12381
    1. Zhang DF, Zhang J, Li R. Magnesium salvianolate B attenuates lung inflammation induced by cigarette smoke in mice. Eur J Pharmacol. 2015;761: 174–179. 10.1016/j.ejphar.2015.05.003
    1. Chen CG, Wang YP. Magnesium lithospermate B ameliorates renal cortical microperfusion in rats. Acta Pharmacol Sin. 2006;27: 217–222. 10.1111/j.1745-7254.2006.00225.x
    1. Lee GT, Ha H, Jung M, Li H, Hong SW, Cha BS, et al. Delayed treatment with lithospermate B attenuates experimental diabetic renal injury. J Am Soc Nephrol. 2003;14: 709–720.
    1. Fang C, Ren X, Zhou H, Gong ZC, Shen L, Bai J, et al. Effects of eNOS rs1799983 and ACE rs4646994 polymorphisms on the therapeutic efficacy of SMDS injection in Chinese patients with coronary heart disease. Clin Exp Pharmacol Physiol. 2014;41: 558–564. 10.1111/1440-1681.12257

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe